Pharmamel
Developing skincare products with melatonina and CoQ10 for facial regeneration and intensive cellular repair, and researching melatonina injections to prevent mortality in COVID-19 hospitalized patients.
Launch date
Employees
Market cap
-
Enterprise valuation
€31m (Public information from May 2023)
Company register number B13735246
Granada Andalusia (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
| % growth | 59 % | 74 % | (4 %) | (50 %) | (7 %) | - | - |
| EBITDA | (<1m) | <1m | <1m | (<1m) | (<1m) | - | - |
| % EBITDA margin | (5 %) | 12 % | 12 % | (52 %) | (91 %) | - | - |
| Profit | <1m | <1m | <1m | <1m | (<1m) | - | - |
| % profit margin | 1 % | 4 % | 5 % | 51 % | (169 %) | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
* | €100k | Seed | |
$100k | Debt | ||
* | €3.6m Valuation: €31.0m | Seed | |
| Total Funding | €3.7m | ||
Related Content
Recent News about Pharmamel
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.